Abstract: In order to ensure the safety of the public′s medication， developed countries such as Europe and the United States have established a relatively complete post-marketing safety monitoring system. In particular， active monitoring after listing not only makes up for the shortcomings of traditional spontaneous reporting， but also provides a basis for subsequent pharmacovigilance activities. Therefore， this paper is concerned with active monitoring in ICH-E2E， EU GVP Guidelines， US Pharmacovigilance Practices and Epidemiological Guidelines， Post-marketing Research and Clinical Trials - 505(o)(3) .The method is combed and analyzed to provide reference for the construction of active drug monitoring methods in China.